Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01614210 · ClinicalTrials.gov registry record · Phase 2
Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance
A Phase 2 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01614210 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 52 participants.
The verdict
NCT01614210, a Phase 2 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of the study is to see if tumors respond to endocrine therapy by taking a total of 21 doses of Tamoxifen before and after surgery. Tamoxifen is currently approved by the FDA (Food and Drug Administration) for use in the treatment of hormone positive breast cancer.
Interventions
- DRUG Tamoxifen
- PROCEDURE Breast cancer surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01614210
The ClinicalTrials.gov registry entry for NCT01614210 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.
NCT01614210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01614210 about?
NCT01614210 is a clinical study titled "Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance". The purpose of the study is to see if tumors respond to endocrine therapy by taking a total of 21 doses of Tamoxifen before and after surgery. Tamoxifen is currently approved by the FDA (Food and Drug Administration) for use in the treatment of hormone positive breast cancer.
What is the current status of trial NCT01614210?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2012-08. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01614210?
The interventions under investigation include: Tamoxifen (DRUG), Breast cancer surgery (PROCEDURE).
Who is sponsoring clinical trial NCT01614210?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.